Boping Liu

10 Biopolis Road, Chromos #05-01
Singapore, 138670, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity".

Correction to "Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity".

Journal: Journal of medicinal chemistry

Published: December 23, 2025

Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity.

Discovery of an Orally Bioavailable Reversible Covalent SARS-CoV-2 Mpro Inhibitor with Pan-Coronavirus Activity.

Journal: Journal of medicinal chemistry

Published: August 07, 2025

A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.

A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.

Journal: ACS medicinal chemistry letters

Published: May 31, 2022

Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.

Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: July 16, 2021

A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.

A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: May 29, 2021

Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*.

Strategic Design of Catalytic Lysine-Targeting Reversible Covalent BCR-ABL Inhibitors*.

Journal: Angewandte Chemie (International ed. in English)

Published: April 20, 2021

Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.

Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.

Journal: Journal of medicinal chemistry

Published: January 08, 2020

Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues.

Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues.

Journal: ACS medicinal chemistry letters

Published: November 12, 2018

Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.

Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.

Journal: Journal of medicinal chemistry

Published: April 25, 2018

Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.

Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.

Journal: Journal of medicinal chemistry

Published: April 24, 2018

Correction to Probing the Binding Mechanism of Mnk Inhibitors by Docking and Molecular Dynamics Simulations.

Correction to Probing the Binding Mechanism of Mnk Inhibitors by Docking and Molecular Dynamics Simulations.

Journal: Biochemistry

Published: October 28, 2017

Escherichia coli Topoisomerase IV E Subunit and an Inhibitor Binding Mode Revealed by NMR Spectroscopy.

Escherichia coli Topoisomerase IV E Subunit and an Inhibitor Binding Mode Revealed by NMR Spectroscopy.

Journal: The Journal of biological chemistry

Published: May 10, 2016

Showing 1-12 of 18

Last Updated: 09/26/2026